T. Rowe Price Associates
CLRB icon

T. Rowe Price Associates’s Cellectar Biosciences CLRB Stock Holding History

T. Rowe Price Associates’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-139
Closed -$28K – 2986
2021
Q4 		$28K Hold
139
– – ﹤0.01% 2953
2021
Q3 		$39K Buy
+139
New +$42.4K ﹤0.01% 2914

Other funds holding CLRB

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates's CLRB Position: Q1 2022 in Review

T. Rowe Price Associates sold out of Cellectar Biosciences (CLRB) in Q1 2022, closing a stake of 139 shares — an estimated $28K sold.

T. Rowe Price Associates first reported a position in CLRB in Q3 2021 and held it in 2 quarters. The position peaked at $39K in Q3 2021. 30 funds tracked by Wall St. Rank hold CLRB as of Q1 2022.

  • T. Rowe Price Associates reported no remaining Cellectar Biosciences position as of Q1 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 139 Cellectar Biosciences shares in Q1 2022, an estimated $28K.
  • T. Rowe Price Associates first reported a position in Cellectar Biosciences in Q3 2021 and held it in 2 quarters.
  • T. Rowe Price Associates's Cellectar Biosciences position peaked at $39K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2022.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.